Category: Pharmaceuticals and Biotech
PharmaNest Inc. announced today a multi-institutional research collaboration with Virginia Commonwealth University (VCU) and the National Institutes of Health (NIH) to confirm the prognostic performance of artificial intelligence (AI) powered digital pathology biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD) in a retrospective cohort of 1,765 patients with MASH (NASH CRN DB2 Cohort)
FibroMAP combines the power of high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's digital pathology and image analysis platform (FibroNest) with advanced clustering techniques such as Uniform Manifold Approximation and Projection (UMAP) to interpret complex, high-dimensional data. FibroMAP is poised to revolutionize the study of fibrosis histology in the same way that single-cell analysis transformed biology.
New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021